We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Influenza-Like Illness Surveyed in the United States

By LabMedica International staff writers
Posted on 26 Jan 2010
A surveillance network summarized U.S. More...
influenza activity from August 30, 2009, through January 9, 2010.

The 2009 pandemic influenza A virus H1N1, the cause of substantial disease worldwide, emerged in the United States in April 2009. During August 30, 2009-January 9, 2010, the World Health Organization (WHO; Geneva, Switzerland) and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories in the United States tested 310,151 respiratory specimens for influenza viruses. Of those 81,179 (26.2%) were positive, and 80,951 (99.7%) of these were positive for influenza A, and 228 (0.3%) were positive for influenza B. Of the 61,726 influenza A viruses for which subtyping was performed, 61,332 (99.4%) were 2009 H1N1 viruses. Only 29 viruses (<0.1%) were seasonal influenza A (H1), 52 (<0.1%) were influenza A (H3) viruses, and 313 (0.5%) were influenza A, but were not subtyped because of specimen quantity or quality.

The emergence and spread of the 2009 pandemic influenza A virus H1N1 (2009 H1N1) resulted in much higher than usual influenza activity in the United States throughout the summer and fall months of 2009. During this period, influenza activity reached its highest level in the week ending October 24, 2009, with 49 of 50 states reporting geographically widespread disease. By January 9, 2010, overall influenza activity declined substantially. Since April 2009, the dominant circulating influenza virus in the United States was Influenza A virus H1N1 2009.

During the surveillance period declines were observed in 2009 H1N1 influenza activity; however, rates of influenza-related hospitalizations and deaths among persons aged < 65 years during this season were substantially higher than in previous influenza seasons.

The Council of State and Territorial Epidemiologists (CSTE) instituted reporting of 2009 H1N1-confirmed hospitalizations and deaths to the Center for Disease Control and Prevention (CDC; Atlanta, GA, USA). On August 30, 2009, CDC and CSTE instituted modified case definitions for aggregate reporting of influenza-associated hospitalizations and deaths.

CDC antigenically characterized 944 viruses that were 2009 H1N1, one seasonal influenza A virus, seven influenza A (H3N2), and six influenza B viruses collected since September 1, 2009. A total of 942 (99.8%) 2009 H1N1 viruses tested were related to the A/California/7/2009 (H1N1) reference virus selected by WHO as the 2009 H1N1 vaccine virus; only two viruses (0.2%) showed reduced titers with antisera produced against A/California/7/2009.

Surveillance for resistance of circulating influenza viruses to both classes of influenza antiviral medications: adamantanes (amantadine and rimantadine) and neuraminidase inhibitors (zanamivir and oseltamivir) were conducted by CDC.

The largest number of states to date reporting widespread activity occurred during the week ending October 24, 2009, when 49 jurisdictions reported widespread activity. During the week ending January 9, 2010, no jurisdiction reported widespread activity. The early widespread state-specific activity contrasts with the previous three influenza seasons (October to May), when state-specific influenza activity did not reach comparable levels until mid-February or early March.

In the week ending October 24, 2009, the weekly percentage of outpatient visits for influenza-like illness (ILI) reported by the U.S. Outpatient ILI Surveillance Network (ILINet) reached 7.7%, the highest level to date this influenza season. By January 9, 2010, ILI activity had decreased to 1.9%. During the previous three influenza seasons, peak ILI activity occurred later in the season and ranged from 3.5% during the week ending February 17 of the 2006-07 seasons to 6.0% during the week ending February 17 of the 2007-08 season.

During August 30, 2009-January 9, 2010, 1,779 deaths associated with laboratory-confirmed influenza virus infections were reported to CDC. The 1,779 laboratory-confirmed deaths were in addition to the 593 laboratory-confirmed deaths from 2009 H1N1 that were reported to CDC from April through August 30, 2009.

Epidemiologic data in this report support expanded recommendations by CDC that the influenza A (H1N1) 2009 monovalent vaccine be offered to all persons aged 6 months or older, depending on local availability. The report appeared online in CDC's Morbidity and Mortality Weekly Report (MMWR) on January 22, 2010.

Related Links:
World Health Organization
Center for Disease Control and Prevention
National Respiratory and Enteric Virus Surveillance System
Council of State and Territorial Epidemiologists
Outpatient ILI Surveillance Network


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The VITROS hs Troponin I Assay is designed for use on VITROS Systems (Photo courtesy of QuidelOrtho)

High-Sensitivity Troponin I Assay Aids in Diagnosis of Myocardial Infarction

Heart disease remains the leading cause of death for adults over 45 in the United States, accounting for nearly one in three deaths. In 2023 alone, 919,032 Americans died from cardiovascular disease —... Read more

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.